Hemispherix Dead Tired (HEB)

Posted in pre-market 
December 2nd, 2009

Hemispherx Biopharma, Inc. (AMEX: HEB) lost almost half of its value last night and is still getting crushed this morning.  The company announced that the FDA has denied its Ampligen treatment as a treatment for chronic fatigue syndrome.  The FDA said the two key studies did not prove the drugs efficacy and recommended that another study be conducted.  At 8:08 AM EST we have seen 360,000 shares trade hands and the stock is down 46% at $0.649.  Average volume is 3.7 million shares and the 52-week range is $0.26 to $4.54.

JON OGG

Comments are closed

-->